Literature DB >> 19125679

Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006.

Andrew M Ramsey1, Marya D Zilberberg.   

Abstract

Although the incidence of hospitalizations with infection due to vancomycin-resistant pathogens in the United States remained stable during 2000-2003, it increased from 4.60 to 9.48 hospitalizations per 100,000 population during 2003-2006. Hospitalizations with infection due to vancomycin-resistant pathogens also increased as a proportion of all US hospitalizations, from 3.16 to 6.51 hospitalizations with VRE infection per 10,000 total hospitalizations during 2003-2006. The number of hospitalizations with infection due to vancomycin-resistant pathogens is increasing in the United States. Because infection due to vancomycin-resistant organisms is associated with poor outcomes, the epidemiology of this trend needs further exploration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125679     DOI: 10.1086/593956

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  37 in total

1.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

2.  Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia.

Authors:  Nicholas S Britt; Emily M Potter; Nimish Patel; Molly E Steed
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Controlling a vancomycin-resistant enterococci outbreak in a Brazilian teaching hospital.

Authors:  M L Moretti; L G de Oliveira Cardoso; C E Levy; A Von Nowakosky; L F Bachur; O Bratfich; M L Leichsenring; R Fagnani; S M Peres Evangelista Dantas; M R Resende; P Trabasso
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-24       Impact factor: 3.267

4.  A small-molecule antivirulence agent for treating Clostridium difficile infection.

Authors:  Kristina Oresic Bender; Megan Garland; Jessica A Ferreyra; Andrew J Hryckowian; Matthew A Child; Aaron W Puri; David E Solow-Cordero; Steven K Higginbottom; Ehud Segal; Niaz Banaei; Aimee Shen; Justin L Sonnenburg; Matthew Bogyo
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

5.  Clinical epidemiology of vancomycin-resistant Enterococcus gallinarum and Enterococcus casseliflavus bloodstream infections.

Authors:  Nicholas S Britt; Emily M Potter
Journal:  J Glob Antimicrob Resist       Date:  2015-12-21       Impact factor: 4.035

Review 6.  Body mass index and outcomes from pancreatic resection: a review and meta-analysis.

Authors:  Andrew M Ramsey; Robert C Martin
Journal:  J Gastrointest Surg       Date:  2011-04-12       Impact factor: 3.452

Review 7.  Hospital epidemiology and infection control in acute-care settings.

Authors:  Emily R M Sydnor; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

8.  Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.

Authors:  Nicholas S Britt; Emily M Potter; Nimish Patel; Molly E Steed
Journal:  Clin Infect Dis       Date:  2015-06-10       Impact factor: 9.079

9.  The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Rosemary Soave; Alexandra C Racanelli; Tsiporah B Shore; Koen van Besien; Stephen G Jenkins; Thomas J Walsh
Journal:  Leuk Lymphoma       Date:  2014-03-24

Review 10.  Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.

Authors:  Marya D Zilberberg; Joyce Chen; Samir H Mody; Andrew M Ramsey; Andrew F Shorr
Journal:  BMC Pulm Med       Date:  2010-08-26       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.